Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription 31.08.2020 1 AJR Am J Roentgenol 1 BMC Cancer 1 Br J Radiol 2 Clin Cancer Res 1 Eur Radiol 5 Eur Urol 1 Int J Cancer 2 J Clin Oncol 2 J Magn Reson Imaging 2 J Natl Cancer Inst 11 J Urol 3 N Engl J Med 2 PLoS One 2 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. DHATT R, Choy S, Co SJ, Ischia J, et al
   MRI of the Prostate With and Without Endorectal Coil at 3 T: Correlation With Whole-Mount Histopathologic Gleason Score.
   AJR Am J Roentgenol. 2020 Mar 11:1-9. doi: 10.2214/AJR.19.22094.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. IGARASHI K, Yui Y, Watanabe K, Kumai J, et al
   Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells.
   BMC Cancer. 2020;20:802.
   PubMed         Abstract available
   
   

   
   Br J Radiol

3. YAN M, Moideen N, Bratti VF, Moraes FY, et al
   Stereotactic body radiotherapy (SBRT) in metachronousoligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence.
   Br J Radiol. 2020 Aug 21:20200496. doi: 10.1259/bjr.20200496.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

4. MUNIYAN S, Rachagani S, Parte S, Halder S, et al
   Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling.
   Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1569.
   PubMed         Abstract available
   
   
5. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
   Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
   Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
   PubMed         Abstract available
   
   

   
   Eur Radiol

6. GUGLIANDOLO SG, Pepa M, Isaksson LJ, Marvaso G, et al
   MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).
   Eur Radiol. 2020 Aug 27. pii: 10.1007/s00330-020-07105.
   PubMed         Abstract available
   
   

   
   Eur Urol

7. ANING J, McCoubrie P, Oxley J
   Re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Patholo
   Eur Urol. 2020 Aug 21. pii: S0302-2838(20)30607.
   PubMed        
   
   
8. VAN LEENDERS GJLH, van der Kwast TH, Iczkowski KA
   The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading.
   Eur Urol. 2020 Aug 23. pii: S0302-2838(20)30618.
   PubMed         Abstract available
   
   
9. RADTKE JP, Nyarangi-Dix J, Wiesenfarth M, Hadaschik B, et al
   Re: The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Pr
   Eur Urol. 2020 Aug 23. pii: S0302-2838(20)30636.
   PubMed        
   
   
10. SHORE ND, Dearnaley D, Tombal B
    Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-9
    Eur Urol. 2020 Aug 21. pii: S0302-2838(20)30606.
    PubMed        
    
    
11. MORIS L, Mottet N, Wiegel T
    Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostat
    Eur Urol. 2020 Aug 21. pii: S0302-2838(20)30621.
    PubMed        
    
    

    
    Int J Cancer

12. OUTZEN M, Tjonneland A, Hughes DJ, Jenab M, et al
    Toenail selenium, plasma selenoprotein P and risk of advanced prostate cancer: a nested case-control study.
    Int J Cancer. 2020 Aug 24. doi: 10.1002/ijc.33267.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

13. VICKERS AJ
    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:653-654.
    PubMed        
    
    
14. AGOCHUKWU NQ, Wittmann D, Boileau NR, Dunn RL, et al
    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:654-655.
    PubMed        
    
    

    
    J Magn Reson Imaging

15. STEENSMA BR, Luttje M, Voogt IJ, Klomp DWJ, et al
    Comparing signal-to-noise ratio for prostate imaging at 7T and 3T.
    J Magn Reson Imaging. 2018 Oct 22. doi: 10.1002/jmri.26527.
    PubMed         Abstract available
    
    
16. PRABHU V, Rosenkrantz AB, Otazo R, Sodickson DK, et al
    Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
    J Magn Reson Imaging. 2019 Jan 10. doi: 10.1002/jmri.26318.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

17. DARST BF, Dadaev T, Saunders E, Sheng X, et al
    Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.
    J Natl Cancer Inst. 2020 Aug 27. pii: 5898200. doi: 10.1093.
    PubMed         Abstract available
    
    
18. DRAGO JZ, Gonen M, Thanarajasingam G, Sacks CA, et al
    Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer.
    J Natl Cancer Inst. 2020 Aug 28. pii: 5898636. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Urol

19. MOTTERLE G, Ahmed ME, Andrews JR, Moschini M, et al
    Tumor Seeding after Robot-Assisted Radical Prostatectomy: Literature Review and Experience from a Single Institution.
    J Urol. 2020;203:1141-1146.
    PubMed         Abstract available
    
    
20. KAOUK J, Aminsharifi A, Wilson CA, Sawczyn G, et al
    Extraperitoneal versus Transperitoneal Single Port Robotic Radical Prostatectomy: A Comparative Analysis of Perioperative Outcomes.
    J Urol. 2020;203:1135-1140.
    PubMed         Abstract available
    
    
21. FULLER TW, Ballon-Landa E, Gallo K, Smith TG 3rd, et al
    Outcomes and Risk Factors of Revision and Replacement Artificial Urinary Sphincter Implantation in Radiated and Nonradiated Cases.
    J Urol. 2020;204:110-114.
    PubMed         Abstract available
    
    
22. ATALA A
    Re: Genome-Wide Plasma DNA Methylation Features of Metastatic Prostate Cancer.
    J Urol. 2020 Aug 21:101097JU000000000000126301.
    PubMed        
    
    
23. SARI MOTLAGH R, Quhal F, Mori K, Miura N, et al
    The Risk of New Onset Dementia And/Or Alzheimer's Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2020 Aug 28:101097JU0000000000001341. doi: 10.1097/JU.0000000000001341.
    PubMed         Abstract available
    
    
24. GRIEBLING TL
    Re: Frailty Syndrome is Associated with Changes in Peripheral Inflammatory Markers in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.
    J Urol. 2020 Aug 26:101097JU000000000000124803.
    PubMed        
    
    
25. GRIEBLING TL
    Re: Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia.
    J Urol. 2020 Aug 26:101097JU000000000000124804.
    PubMed        
    
    
26. GRIEBLING TL
    Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
    J Urol. 2020 Aug 26:101097JU0000000000001248. doi: 10.1097/JU.0000000000001248.
    PubMed        
    
    
27. GRIEBLING TL
    Re: Pre-Diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival.
    J Urol. 2020 Aug 26:101097JU000000000000124801.
    PubMed        
    
    
28. GRIEBLING TL
    Re: Clinical-Genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-Grade Disease.
    J Urol. 2020 Aug 26:101097JU000000000000124802.
    PubMed        
    
    
29. ATALA A
    Re: Noncoding Mutations Target Cis-Regulatory Elements of the FOXA1 Plexus in Prostate Cancer.
    J Urol. 2020 Aug 21:101097JU0000000000001263. doi: 10.1097/JU.0000000000001263.
    PubMed        
    
    

    
    N Engl J Med

30. MUTETWA T, Foulkes WD, Polak P
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020;383:890.
    PubMed        
    
    
31. HEIDEGGER I, Pircher A
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020;383:890-891.
    PubMed        
    
    
32. DE BONO J, Kang J, Hussain M
    Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply.
    N Engl J Med. 2020;383:891.
    PubMed        
    
    

    
    PLoS One

33. YAMADA Y, Teshima T, Fujimura T, Sato Y, et al
    Comparison of perioperative outcomes in elderly (age >== 75 years) vs. younger men undergoing robot-assisted radical prostatectomy.
    PLoS One. 2020;15:e0234113.
    PubMed         Abstract available
    
    
34. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed         Abstract available
    
    

    
    Prostate

35. WIGGINS EK, Oyekunle T, Howard LE, Markt SC, et al
    Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial.
    Prostate. 2020 Aug 24. doi: 10.1002/pros.24052.
    PubMed         Abstract available
    
    
36. MCALLISTER M, Constancio V, Patek S, Gan H, et al
    Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naive prostate cancer.
    Prostate. 2020 Aug 26. doi: 10.1002/pros.24064.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: